三个皮匠报告—— 严选型全行业研究报告分享下载平台，您的专属行业智库！
欢迎来到三个皮匠报告！
登录
帮助中心
首页
最新
研搜
BETA
合集
英文
会议
数据
财报库
政策库
自研报告
入驻
您的当前位置：
首页
>
行业数据
>
发生FGFR突变的肿瘤比例
发生FGFR突变的肿瘤比例
行业数据
下载Excel
下载图片
原图定位
图片属性
图片格式：PNG
图片大小：79KB
图片尺寸：1151*751
同报告图片
/
4
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
PHRhYmxlPgogICAgPHRoZWFkPgogICAgICAgIDx0cj4KICAgICAgICAgICAgYGBgaHRtbAo8dGg+6I2v54mpPC90aD4KICAgICAgICAgICAgPHRoPueglOWPkeS8geS4mjwvdGg+CiAgICAgICAgICAgIDx0aD7pgILlupTnl4c8L3RoPgogICAgICAgICAgICA8dGg+5Li05bqK6K+V6aqM6Zi25q61PC90aD4KICAgICAgICA8L3RyPgogICAgPC90aGVhZD4KICAgIDx0Ym9keT4KICAgICAgICA8dHI+CiAgICAgICAgICAgIDx0ZD5FbnRyZWN0aW5pYjwvdGQ+CiAgICAgICAgICAgIDx0ZD7nvZfmsI88L3RkPgogICAgICAgICAgICA8dGQ+5a6e5L2T55ikPC90ZD4KICAgICAgICAgICAgPHRkPuKFoeacnzwvdGQ+CiAgICAgICAgPC90cj4KICAgICAgICA8dHI+CiAgICAgICAgICAgIDx0ZD5UYWxldHJlY3RpbmliPC90ZD4KICAgICAgICAgICAgPHRkPuiRhuWFg+WMu+iNrzwvdGQ+CiAgICAgICAgICAgIDx0ZD7lrp7kvZPnmKQ8L3RkPgogICAgICAgICAgICA8dGQ+4oWh5pyfPC90ZD4KICAgICAgICA8L3RyPgogICAgICAgIDx0cj4KICAgICAgICAgICAgPHRkPlJlcG90cmVjdGluaWI8L3RkPgogICAgICAgICAgICA8dGQ+VHVybmluZyBQb2ludCBUaGVyYXBldXRpY3M8L3RkPgogICAgICAgICAgICA8dGQ+5a6e5L2T55ikPC90ZD4KICAgICAgICAgICAgPHRkPuKFoC/ihaHmnJ88L3RkPgogICAgICAgIDwvdHI+CiAgICAgICAgPHRyPgogICAgICAgICAgICA8dGQ+U2VsaXRyZWN0aW5pYjwvdGQ+CiAgICAgICAgICAgIDx0ZD7mi5zogLM8L3RkPgogICAgICAgICAgICA8dGQ+5a6e5L2T55ikPC90ZD4KICAgICAgICAgICAgPHRkPuKFoC/ihaHmnJ88L3RkPgogICAgICAgIDwvdHI+CiAgICAgICAgPHRyPgogICAgICAgICAgICA8dGQ+SUNQIC0gNzIzPC90ZD4KICAgICAgICAgICAgPHRkPuivuuivmuWBpeWNjjwvdGQ+CiAgICAgICAgICAgIDx0ZD7lrp7kvZPnmKQ8L3RkPgogICAgICAgICAgICA8dGQ+4oWgL+KFoeacnzwvdGQ+CiAgICAgICAgPC90cj4KICAgICAgICA8dHI+CiAgICAgICAgICAgIDx0ZD5IRyAtIDAzMDwvdGQ+CiAgICAgICAgICAgIDx0ZD7miJDpg73lhYjlr7w8L3RkPgogICAgICAgICAgICA8dGQ+5a6e5L2T55ikPC90ZD4KICAgICAgICAgICAgPHRkPuKFoOacnzwvdGQ+CiAgICAgICAgPC90cj4KICAgICAgICA8dHI+CiAgICAgICAgICAgIDx0ZD5CUEkgLSAyODU5MjwvdGQ+CiAgICAgICAgICAgIDx0ZD7otJ3ovr7oja/kuJo8L3RkPgogICAgICAgICAgICA8dGQ+5a6e5L2T55ikPC90ZD4KICAgICAgICAgICAgPHRkPuKFoOacnzwvdGQ+CiAgICAgICAgPC90cj4KICAgICAgICA8dHI+CiAgICAgICAgICAgIDx0ZD5GQ04gLSAwMTE8L3RkPgogICAgICAgICAgICA8dGQ+5aSN5pif5Yy76I2vPC90ZD4KICAgICAgICAgICAgPHRkPuWunuS9k+eYpDwvdGQ+CiAgICAgICAgICAgIDx0ZD7ihaDmnJ88L3RkPgogICAgICAgIDwvdHI+CiAgICAgICAgPHRyPgogICAgICAgICAgICA8dGQ+TFBNIC0gNDg3MDEwODwvdGQ+CiAgICAgICAgICAgIDx0ZD7nu7/lj7bliLboja88L3RkPgogICAgICAgICAgICA8dGQ+5a6e5L2T55ikPC90ZD4KICAgICAgICAgICAgPHRkPuKFoOacnzwvdGQ+CiAgICAgICAgPC90cj4KICAgIDwvdGJvZHk+CjwvdGFibGU+CgrotYTmlpnmnaXmupA6IOWMu+iNr+mtlOaWuSwgQ0RFLCDlhYnlpKfor4HliLjnoJTnqbbmiYAKYGBg
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
所属报告：
诺诚健华-投资价值分析报告：奥势即达随宜而安创新药企新秀崛起-210909（37页）.pdf
打包全文图表
相关数据
anti-FGFR2b单抗与SOS1抑制剂国内临床进展
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
收藏
行业数据
2025-12-31
原图定位
查看详情
FGFR2基因的三种不同突变类型：融合，点突
PHxiZWdpbl9vZl9ib3h8PnwgRkdGUjLnqoHlj5gv5pS55Y+Y57G75Z6LICAgICAgIHwg576O5Zu95bm05Y+R55eF5Lq65pWwICAgICAgICAgfAp8LS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tfAp8IEZ1c2lvbu+8iOiejeWQiO+8iSAgICAgICAgICAgfCB+NC41SyAtIDE0SyAgICAgICAgICAgIHwKfCBNdXRhdGlvbu+8iOeCueeqgeWPmO+8iSAgICAgICB8IH42LjVLIC0gMjFLICAgICAgICAgICAgfAp8IFRvdGFsIEZHRlIyIGFsdGVyYXRpb25zICB8IH4xMSAtIDM1SyBwYXRpZW50cyAgICAgfAoK6LWE5paZ5p2l5rqQ77ya6Ieq54S26IK/55ik5a2m57u86L+w5p2C5b+XMjAxNzx8ZW5kX29mX2JveHw+
收藏
行业数据
2025-10-10
原图定位
查看详情
美国FGFR2基因突变在不同实体瘤的发病人数
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
收藏
行业数据
2025-10-10
原图定位
查看详情
全球首个FGFR4抑制剂联合IO在HCC的临床设计：依帕戈替尼联合阿替利珠单抗的临床二期试验方案
PHxiZWdpbl9vZl9ib3h8PnwgUGFydCB8IERvc2UgUmVnaW1lbiAgICAgICB8IFNhbXBsZSBTaXplIChOKSB8CnwtLS0tLS18LS0tLS0tLS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS0tLS18CnwgQSAgICB8IDE4MG1nIFFEICAgICAgICAgICB8IDYgICAgICAgICAgICAgICB8CnwgQSAgICB8IDMyMG1nIFFEICAgICAgICAgICB8IDYgICAgICAgICAgICAgICB8CnwgQSAgICB8IDE2MG1nIEJJRCAgICAgICAgICB8IDggICAgICAgICAgICAgICB8CnwgQSAgICB8IDIyMG1nIEJJRCAgICAgICAgICB8IDMzICAgICAgICAgICAgICB8CgrotYTmlpnmnaXmupDvvJrlhazlj7hQUFQ8fGVuZF9vZl9ib3h8Pg==
收藏
行业数据
2025-10-10
原图定位
查看详情
全球几款早于和誉依帕戈替尼进入临床阶段的FGFR4抑制剂，大部分都已经停止开发
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
收藏
行业数据
2025-10-10
原图定位
查看详情
和誉FGFR2/3抑制剂将针对胃癌和软骨发育不全症两个适应症展开
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
收藏
行业数据
2025-10-10
原图定位
查看详情
全球主要已经上市获批的FGFR抑制剂销售及未来销售预测
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
收藏
行业数据
2025-10-10
原图定位
查看详情
全球约30%的肝细胞癌患者存在异常的FGF19-FGFR4通路改变，依帕戈替尼（ABSK011）的独特设计MoA
fCDlnLDljLogICB8IOavj+W5tOaWsOWinueXheS+i+aVsCB8CnwtLS0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tfAp8IOWFqOeQgyAgIHwg57qmMzDkuIcgICAgICAgICB8Cnwg5Lit5Zu9ICAgfCDnuqYxNeS4hyAgICAgICAgIHwKCui1hOaWmeadpea6kO+8muWFrOWPuFBQVO+8jOS+neW4leaIiOabv+WwvOmAmui/h+mdtuWQkUZHRjE5IC0gRkdGUjQg6YCa6Lev5rK755aX6IKd55mM
收藏
行业数据
2025-10-10
原图定位
查看详情
FGFR家族的主要四类亚型，在人体不同类型癌症中的突变类型（基因扩增/点突变/基因融合重排）
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
收藏
行业数据
2025-10-10
原图定位
查看详情
全球在研的FGFR2b单抗产品
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
收藏
行业数据
2025-09-24
原图定位
查看详情
用于胃癌治疗的FGFR靶点药物竞争格局
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
收藏
竞争格局
2025-09-19
原图定位
查看详情
全球在研FGFR2bADC
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
收藏
行业数据
2025-07-07
原图定位
查看详情
图表30FGFR4与FGFR1-3结构差异
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
收藏
行业数据
2025-04-11
原图定位
查看详情
FGFR信号通路以及抑制剂
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
收藏
行业数据
2024-12-09
原图定位
查看详情
全球已上市选择性FGFR小分子抑制剂
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
收藏
行业数据
2024-12-09
原图定位
查看详情
最新数据
全球全年龄段奶粉市场规模（亿美元）
收藏
行业数据
2026-07-30
原图定位
查看详情
全球酸奶及发酵乳制品市场规模（亿美元）
收藏
行业数据
2026-07-30
原图定位
查看详情
全球药用级益生菌市场规模（百万美元）
收藏
行业数据
2026-07-30
原图定位
查看详情
全球益生菌膳食补充剂市场规模及增速
收藏
行业数据
2026-07-30
原图定位
查看详情
全球拥有AKK专利菌株的核心企业
收藏
行业数据
2026-07-30
原图定位
查看详情
根据文献 Clinical Cancer Research2016 年对于实体瘤的统计结果显示，在所有类型的实体瘤中，有 7.1%来自于 FGFR 突变。F&S 对全球 FGFR 突变导致的实体瘤不同类型发生病例数进行了统计。截至 2018 年，乳腺癌、尿路上皮癌（膀胱癌最常见的病理类型）、肝细胞癌等发病人数居前。尿路上皮癌和胆管癌是发生 FRFR1-4 突变比例最高的肿瘤类型。
行业数据
原图定位
当前图表所属：
诺诚健华-投资价值分析报告：奥势即达随宜而安创新药企新秀崛起-210909（37页）.pdf
公司已披露靶点的候选药物汇总
国内在研的泛TRK抑制剂汇总
国内在研的FGFR4抑制剂针对肝细胞癌适应症汇总
国内在研的（II期及以上）FGFR抑制剂针对尿路上皮癌和胆管癌适应症汇总
下载图片或Excel，需升级至尊VIP会员或「预见者」VIP
立即去升级
客服
商务合作
小程序
服务号
回到顶部
折叠
微信扫码登录
微信扫码登录
双重福利，扫码领取！
关注公众号『三个皮匠报告』，免费领取报告
1.100+最新优质行业报告
2.每周免费精选报告分享
手机快捷登录
账号登录
记住密码
忘记密码？
验证即登录，未注册将自动创建账号
获取验证码
收不到验证码注意事项
登录代表您已阅读并同意
《三个皮匠服务条款》
研搜
0731-84720580
商务合作：really158d
下载Excel
下载图片
原图定位
打包全文图表
收藏
2025-12-31
原图定位
微信扫码登录
手机快捷登录
账号登录
